# Revolution Medicines, Inc.: financial statements, quarterly

RVMD · Nasdaq · CIK 1628171 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rvmd.md) · [Financials](/companies/rvmd/financials.md) · [Filings](/companies/rvmd/filings.md) · [Insiders](/companies/rvmd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rvmd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0000950170-24-122303.md) | [0.7 d](/filings/0001193125-26-071563.md) | [0.0](/filings/0000950170-24-055655.md) | [0.0](/filings/0000950170-24-092783.md) | [0.0](/filings/0000950170-24-122303.md) | [0.0 d](/filings/0001193125-26-071563.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [108](/filings/0000950170-24-122303.md) | [148 d](/filings/0001193125-26-071563.md) | [118](/filings/0000950170-25-065660.md) | [135](/filings/0000950170-25-104022.md) | [152](/filings/0001193125-25-266923.md) | [188 d](/filings/0001193125-26-071563.md) | [206](/filings/0001193125-26-208969.md) | [224](/filings/0001193125-26-335104.md) | [263](/filings/0001193125-25-266923.md) | [295 d](/filings/0001193125-26-071563.md) | [344](/filings/0001193125-26-208969.md) | [395](/filings/0001193125-26-335104.md) |
| Operating income | $m | [(123)](/filings/0000950170-24-122303.md) | [(180) d](/filings/0001193125-26-071563.md) | [(141)](/filings/0000950170-25-065660.md) | [(157)](/filings/0000950170-25-104022.md) | [(176)](/filings/0001193125-25-266923.md) | [(216) d](/filings/0001193125-26-071563.md) | [(241)](/filings/0001193125-26-208969.md) | [(265)](/filings/0001193125-26-335104.md) | [(315)](/filings/0001193125-25-266923.md) | [(362) d](/filings/0001193125-26-071563.md) | [(445)](/filings/0001193125-26-208969.md) | [(505)](/filings/0001193125-26-335104.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-25-266923.md) | [0.0 d](/filings/0001193125-26-071563.md) | [0.0](/filings/0001193125-26-208969.md) | [0.9](/filings/0001193125-26-335104.md) | [11.4](/filings/0001193125-25-266923.md) | [11.9 d](/filings/0001193125-26-071563.md) | [12.2](/filings/0001193125-26-208969.md) | [23.8](/filings/0001193125-26-335104.md) |
| Income tax | $m | [(3.9)](/filings/0000950170-24-122303.md) | [0.3 d](/filings/0001193125-26-071563.md) | [0.0](/filings/0000950170-24-055655.md) | [0.0](/filings/0000950170-24-092783.md) | [0.0](/filings/0000950170-24-122303.md) | [(0.8) d](/filings/0001193125-26-071563.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(108)](/filings/0000950170-24-122303.md) | [(162) d](/filings/0001193125-26-071563.md) | [(116)](/filings/0001193125-25-266923.md) | [(133)](/filings/0001193125-25-266923.md) | [(156)](/filings/0001193125-25-266923.md) | [(195) d](/filings/0001193125-26-071563.md) | [(213)](/filings/0001193125-26-335104.md) | [(248)](/filings/0001193125-26-335104.md) | [(305)](/filings/0001193125-25-266923.md) | [(365) d](/filings/0001193125-26-071563.md) | [(454)](/filings/0001193125-26-335104.md) | [(644)](/filings/0001193125-26-335104.md) |
| Diluted EPS | $ per share | [(0.99)](/filings/0000950170-24-122303.md) | not reported | [(0.70)](/filings/0000950170-25-065660.md) | [(0.81)](/filings/0000950170-25-104022.md) | [(0.94)](/filings/0001193125-25-266923.md) | not reported | [(1.13)](/filings/0001193125-26-208969.md) | [(1.31)](/filings/0001193125-26-335104.md) | [(1.61)](/filings/0001193125-25-266923.md) | not reported | [(2.29)](/filings/0001193125-26-208969.md) | [(3.06)](/filings/0001193125-26-335104.md) |
| Basic EPS | $ per share | [(0.99)](/filings/0000950170-24-122303.md) | not reported | [(0.70)](/filings/0000950170-25-065660.md) | [(0.81)](/filings/0000950170-25-104022.md) | [(0.94)](/filings/0001193125-25-266923.md) | not reported | [(1.13)](/filings/0001193125-26-208969.md) | [(1.31)](/filings/0001193125-26-335104.md) | [(1.61)](/filings/0001193125-25-266923.md) | not reported | [(2.29)](/filings/0001193125-26-208969.md) | [(3.06)](/filings/0001193125-26-335104.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [358](/filings/0000950170-24-122303.md) | [696](/filings/0001193125-26-071563.md) | [288](/filings/0000950170-25-065660.md) | [276](/filings/0000950170-25-104022.md) | [201](/filings/0001193125-25-266923.md) | [543](/filings/0001193125-26-071563.md) | [334](/filings/0001193125-26-208969.md) | [402](/filings/0001193125-26-335104.md) | [217](/filings/0001193125-25-266923.md) | [384](/filings/0001193125-26-335104.md) | [441](/filings/0001193125-26-208969.md) | [815](/filings/0001193125-26-335104.md) |
| Current assets | $m | [824](/filings/0000950170-23-059391.md) | [1,879](/filings/0000950170-25-027736.md) | [1,729](/filings/0000950170-24-055655.md) | [1,625](/filings/0000950170-24-092783.md) | [1,579](/filings/0000950170-24-122303.md) | [2,328](/filings/0001193125-26-071563.md) | [2,135](/filings/0000950170-25-065660.md) | [2,176](/filings/0000950170-25-104022.md) | [1,977](/filings/0001193125-25-266923.md) | [2,075](/filings/0001193125-26-335104.md) | [1,968](/filings/0001193125-26-208969.md) | [4,028](/filings/0001193125-26-335104.md) |
| Total assets | $m | [984](/filings/0000950170-23-059391.md) | [2,062](/filings/0000950170-25-027736.md) | [1,908](/filings/0000950170-24-055655.md) | [1,808](/filings/0000950170-24-092783.md) | [1,763](/filings/0000950170-24-122303.md) | [2,558](/filings/0001193125-26-071563.md) | [2,365](/filings/0000950170-25-065660.md) | [2,430](/filings/0000950170-25-104022.md) | [2,252](/filings/0001193125-25-266923.md) | [2,355](/filings/0001193125-26-335104.md) | [2,254](/filings/0001193125-26-208969.md) | [4,323](/filings/0001193125-26-335104.md) |
| Current liabilities | $m | [85.5](/filings/0000950170-23-059391.md) | [144](/filings/0000950170-25-027736.md) | [93.7](/filings/0000950170-24-055655.md) | [105](/filings/0000950170-24-092783.md) | [111](/filings/0000950170-24-122303.md) | [164](/filings/0001193125-26-071563.md) | [159](/filings/0000950170-25-065660.md) | [185](/filings/0000950170-25-104022.md) | [246](/filings/0001193125-25-266923.md) | [290](/filings/0001193125-26-335104.md) | [290](/filings/0001193125-26-208969.md) | [354](/filings/0001193125-26-335104.md) |
| Total liabilities | $m | [147](/filings/0000950170-23-059391.md) | [236](/filings/0000950170-25-027736.md) | [183](/filings/0000950170-24-055655.md) | [190](/filings/0000950170-24-092783.md) | [197](/filings/0000950170-24-122303.md) | [293](/filings/0001193125-26-071563.md) | [287](/filings/0000950170-25-065660.md) | [564](/filings/0000950170-25-104022.md) | [655](/filings/0001193125-25-266923.md) | [723](/filings/0001193125-26-335104.md) | [754](/filings/0001193125-26-208969.md) | [1,717](/filings/0001193125-26-335104.md) |
| Shareholders' equity | $m | [837](/filings/0000950170-24-122303.md) | [1,826](/filings/0001193125-26-071563.md) | [1,725](/filings/0001193125-25-266923.md) | [1,619](/filings/0001193125-25-266923.md) | [1,566](/filings/0001193125-25-266923.md) | [2,265](/filings/0001193125-26-335104.md) | [2,078](/filings/0001193125-26-335104.md) | [1,865](/filings/0001193125-26-335104.md) | [1,597](/filings/0001193125-25-266923.md) | [1,631](/filings/0001193125-26-335104.md) | [1,500](/filings/0001193125-26-335104.md) | [2,606](/filings/0001193125-26-335104.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(100) d](/filings/0000950170-24-122303.md) | [(121) d](/filings/0001193125-26-071563.md) | [(161)](/filings/0000950170-25-065660.md) | [(128) d](/filings/0000950170-25-104022.md) | [(130) d](/filings/0001193125-25-266923.md) | [(138) d](/filings/0001193125-26-071563.md) | [(194)](/filings/0001193125-26-208969.md) | [(222) d](/filings/0001193125-26-335104.md) | [(207) d](/filings/0001193125-25-266923.md) | [(274) d](/filings/0001193125-26-071563.md) | [(354)](/filings/0001193125-26-208969.md) | [(387) d](/filings/0001193125-26-335104.md) |
| Capital expenditure | $m | [2.5 d](/filings/0000950170-24-122303.md) | [2.3 d](/filings/0001193125-26-071563.md) | [3.2](/filings/0000950170-25-065660.md) | [2.4 d](/filings/0000950170-25-104022.md) | [3.5 d](/filings/0001193125-25-266923.md) | [1.2 d](/filings/0001193125-26-071563.md) | [3.3](/filings/0001193125-26-208969.md) | [7.5 d](/filings/0001193125-26-335104.md) | [3.3 d](/filings/0001193125-25-266923.md) | [1.9 d](/filings/0001193125-26-071563.md) | [1.5](/filings/0001193125-26-208969.md) | [2.3 d](/filings/0001193125-26-335104.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q1 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [84.7](/filings/0000950170-23-059391.md) | [94.8](/filings/0000950170-24-055655.md) | [107](/filings/0000950170-24-092783.md) | [109](/filings/0000950170-24-122303.md) | [165](/filings/0000950170-25-065660.md) | [165](/filings/0000950170-25-104022.md) | [167](/filings/0001193125-25-266923.md) | [188](/filings/0001193125-26-208969.md) | [189](/filings/0001193125-26-335104.md) | [189](/filings/0001193125-25-266923.md) | [198](/filings/0001193125-26-208969.md) | [211](/filings/0001193125-26-335104.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 214,336,418 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-335104.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.